Astria Therapeutics filings document the company's former Nasdaq-listed common stock, clinical-stage biopharmaceutical operations, material agreements, shareholder voting matters, and completed corporate-status changes. Its 8-K reports covered operating and financial results, the navenibart license agreement for Japan, merger-related agreements, security-holder voting results, and loan-guarantor obligations after the transaction closing.
The filing record also includes Form 25 removal of Astria common stock from Nasdaq listing and Form 15 termination or suspension of Exchange Act reporting duties. Those filings record Astria's transition into a wholly owned subsidiary of BioCryst Pharmaceuticals and the end of separate public-company registration for its common stock.
Astria Therapeutics (ATXS) signed an exclusive license with Kaken Pharmaceutical for Japanese rights to navenibart, its long-acting plasma-kallikrein mAb for hereditary angioedema (HAE). Kaken will lead development, regulatory submissions and commercialization in Japan and will support Astria’s ALPHA-ORBIT Phase 3 trial.
Financial terms: Astria receives a $16 million upfront, up to $16 million in commercial/sales milestones, and tiered royalties ranging from the mid-teens to 30 % of net sales. Royalties run until the later of patent or regulatory exclusivity expiry, or 10 years after first sale.
The upfront plus partial Phase 3 cost reimbursements extend Astria’s cash runway into 2028, covering completion of the Phase 3 program for navenibart and the Phase 1a study of STAR-0310. Management cautions that substantial additional funding will still be needed to finish development and commercialization.
The agreement includes a joint steering committee, Kaken’s right of first negotiation for non-HAE indications, and termination rights for breach, insolvency, safety issues or at Kaken’s convenience (90-day notice).